Jeremic 1997.

Methods	Prospective randomized trial, open‐label Inclusion criteria Histologically or cytologically proven stage IV NSCLC Karnofsky Performance Scale score (KPS) ≥ 50 Measurable or evaluable disease Adequate hematological, hepatic, and renal function Life expectancy ≥ 3 months and no prior therapy Exclusion criteria Recent cardiac disease such as myocardial infarction or uncontrolled congestive heart failure
Participants	E arm: 59 participants/22 participants ≥ 60 years/number of elderly participants not informed CE arm: 58 participants/18 participants ≥ 60 years/number of elderly participants not informed
Interventions	E arm: etoposide 50 mg/m2/d p.o. on days 1 through 21 every 28 days CE arm: carboplatin 400 mg/m2 over 30‐minute i.v. infusion on day 1 and etoposide 50 mg/m2/d p.o. on days 1 through 21 every 28 days
Outcomes	Response rate (according to WHO response criteria) Toxicity according to ECOG criteria Overall survival
Notes	Study prematurely interrupted because chief investigator left the department
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	No information on random sequence generation
Allocation concealment (selection bias)	Unclear risk	No information on allocation concealment
Blinding of outcome assessment (detection bias) OS and 1y OS rate outcome	Unclear risk	No information on blinding of outcome assessment for OS
Blinding of outcome assessment (detection bias) Other outcomes	Unclear risk	No information on blinding of outcome assessment for PFS, ORR, and toxicity
Incomplete outcome data (attrition bias) All outcomes	Low risk	No evidence of attrition bias
Selective reporting (reporting bias)	Low risk	No evidence of reporting bias
Other bias	High risk	Trial prematurely stopped because of personnel problems (chief investigator had to leave department). No information provided for elderly subgroup